STIM logo

NEURONETICS INC

STIMNASDAQ
๐Ÿ† #2875 by market capEarnings Aug 11 ยท PreUS Equity
$3.19โ–ฒ $1.50 (+47.00%)
Live
1hโ€”
24hโ–ฒ 47.0%
7dโ€”
14dโ€”
30dโ€”
1yโ€”
๐ŸฆMarket Cap
$222M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
+69.5%
High Growth
๐Ÿ“ŠGross Margin
48.0%
Healthy
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
1.0x
Cheap
Otter Score
58
Weak
No chart data available for STIM.

Trading Snapshot

Day Range
$3.16 โ€“ $3.23
52-Week Range
$0.80 โ€“ $4.31
Volume
$3.69B
Avg Volume
$3.56B
Shares Outstanding
69.6M
Next Earnings
Sep 2, 2026

Fundamentals Snapshot

Annual Revenue
$149M
Last Q Revenue
$42M
P/E Ratio
โ€”
P/S Ratio
1.0x
EPS (TTM)
$-0.55
Dividend Yield
โ€”

Why Investors Own STIM

  • โœ“High-growth profile โ€” revenue up +46.2% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 75% gross margin and 24% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$149Mโ–ฒ +47.0% YoY
Gross Margin (TTM)
74.5%โ–ฒ +3.9% YoY
Operating Income (TTM)
$28Mโ–ฒ +47.0% YoY
Free Cash Flow (TTM)
$36Mโ–ฒ +47.0% YoY

About NEURONETICS INC

Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
58/100

Analyst Ratings

โ“˜
Consensus
Buy
10 analysts
Strong Buy3
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates